{"database": "lobbying", "table": "lobbying_activities", "rows": [[3052106, "c1dcc04f-3f9f-4a01-9b44-6fa837e952a2", "Q3", "REGENXBIO", 401105178, "REGENXBIO", 2023, "third_quarter", "CPT", "Proposals to change subject matter patent eligibility under Section 101 and other proposals to amend the patent code as they relate to gene therapies and other biopharmaceutical innovations, including: S.2140, the Patent Eligibility Restoration Act and the Coons/Tillis-Buck/Ross PREVAIL Act related to PTO PTAB reform. Assertions of March In Rights under the Bayh-Dole Act or under Section 1498 against biopharmaceutical products. Efforts to impose \"reasonable pricing clauses\" on patent licenses from NIH-grantees to commercial partners. The ongoing PTO-FDA collaboration on drug pricing.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Patent & Trademark Office (PTO),SENATE", null, 94000, 0, 0, "2023-10-16T23:06:24-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3052106"], "units": {}, "query_ms": 0.28790393844246864, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}